Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
- First Online:
- Cite this article as:
- Fabbrini, G., Barbanti, P., Aurilia, C. et al. Neurol Sci (2002) 23: 41. doi:10.1007/s100720200022
- 355 Downloads
As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson’s disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.